Clinical Pharmacology Leader
Pharma Research and Early Development, Roche Innovation Center Basel, Switzerland
Dr. Candice Jamois (PharmD), Clinical Pharmacology Leader at Pharma Research and Early Development (pRED), Roche Innovation Center Basel (Switzerland), brings over 20 years of experience in drug development, specializing in quantitative clinical pharmacology. Since 2012, her work has centered on oncology, where she has contributed to the registration of multiple monoclonal antibodies.
Candice leads the dose selection and optimization strategy for new molecular entities. She applies quantitative clinical pharmacology and model-informed drug development principles throughout the entire drug development process, from first-in-human studies to launch. Candice is an active member of the Roche Dose Optimization Group and the International Consortium (IQ) for Dose Optimization in Oncology Working Group.
Since 2020, inspired by Roche's pRED Digital Transformation and 2030 Vision, Candice has been spearheading the D-Light initiative. This cross-functional project aims to advance Precision Medicine, enhance the likelihood of technical success, accelerate development timelines, and improve decision-making for oncology combination studies; by benchmarking efficacy using early data readouts and leveraging the strengths of pharmacometrics modeling and machine learning.